| Since Halloween is tomorrow, in this week's Safety Net, we're going to take a look at a dividend that many investors are afraid of. For as long as I can remember, Wall Street has been scared silly about AbbVie (NYSE: ABBV). The rub on AbbVie is that Humira, the company's top revenue generator and the biggest-selling drug in the world, is now off-patent. For many years, Wall Street analysts advised investors to stay away, warning that when Humira's patent expired, generics would flood the market and cause AbbVie's revenue, earnings, and stock price to crater as a result. But in reality, the company is as terrifying as a polite 4-year-old trick-or-treater in a princess costume. The chart below shows how wrong Wall Street analysts have been about AbbVie. Even now, more than a third of analysts that cover the stock don't rate it a "Buy." But I never let the "Wrong Way Corrigan" analysts influence me. AbbVie has been in the Compound Income Portfolio in my monthly newsletter, The Oxford Income Letter, since 2016. With dividends reinvested, we're sitting on a gain of 376% and enjoying an annual yield of 10.8% on our original investment. AbbVie is a Perpetual Dividend Raiser, having boosted its dividend every year since it was spun off from Abbott Laboratories (NYSE: ABT) in 2013. It currently pays shareholders a quarterly dividend of $1.55 per share, which gives the stock a 3.3% yield on the current price. Can AbbVie continue to be a Perpetual Dividend Raiser? | 
